News coverage about Alimera Sciences (NASDAQ:ALIM) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alimera Sciences earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 43.4206576952041 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Alimera Sciences (ALIM) traded up $0.09 during trading hours on Tuesday, hitting $1.28. 163,300 shares of the stock traded hands, compared to its average volume of 151,319. Alimera Sciences has a 12 month low of $1.03 and a 12 month high of $1.72. The company has a debt-to-equity ratio of -0.71, a quick ratio of 4.65 and a current ratio of 4.84. The firm has a market cap of $88.51, a PE ratio of -4.13 and a beta of 1.79.
A number of equities analysts have recently commented on ALIM shares. Zacks Investment Research downgraded shares of Alimera Sciences from a “hold” rating to a “sell” rating in a report on Monday, November 27th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Alimera Sciences in a report on Monday, January 22nd. Cowen reissued a “buy” rating on shares of Alimera Sciences in a report on Thursday, November 2nd. Finally, ValuEngine raised shares of Alimera Sciences from a “strong sell” rating to a “sell” rating in a report on Monday, November 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $3.38.
In other news, CEO C. Daniel Myers sold 52,900 shares of Alimera Sciences stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $1.23, for a total transaction of $65,067.00. Following the completion of the sale, the chief executive officer now owns 154,411 shares in the company, valued at approximately $189,925.53. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Philip Ashman sold 25,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $1.23, for a total transaction of $31,365.00. Following the transaction, the senior vice president now owns 38,250 shares of the company’s stock, valued at approximately $47,047.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 184,704 shares of company stock valued at $224,432. 14.70% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Alimera Sciences (NASDAQ:ALIM) Getting Somewhat Favorable Media Coverage, Report Finds” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/20/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-alimera-sciences-alim-share-price.html.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.